HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylclozapine.

AbstractOBJECTIVE:
Clozapine's potent antagonism of muscarinic M1 receptors is thought to worsen working memory deficits associated with schizophrenia. In contrast, its major metabolite, N-desmethylclozapine (NDMC), is thought to enhance working memory via its M1 receptor agonist activity. The authors hypothesized that the ratio of serum clozapine and NDMC concentrations would be inversely associated with working memory performance in schizophrenia.
METHOD:
Thirty patients with schizophrenia or schizoaffective disorder who were receiving clozapine monotherapy at bedtime completed the MATRICS Consensus Cognitive Battery (MCCB) on the day their blood was collected to assess concentrations of clozapine and NDMC as well as serum anticholinergic activity.
RESULTS:
The clozapine/NDMC ratio was significantly and negatively associated with working memory performance after controlling for age, gender, education, and symptom severity. No significant associations were found between individual clozapine and NDMC concentrations and working memory performance. Serum anticholinergic activity was significantly associated with clozapine concentration, but not with working memory performance or NDMC concentration. No significant associations were found between any pharmacological measure and performance on other MCCB cognitive domains.
CONCLUSIONS:
This hypothesis-driven study confirms that clozapine/NDMC ratio is a strong predictor of working memory performance in patients with schizophrenia. This finding suggests that manipulating the clozapine/NDMC ratio could enhance cognition in patients with schizophrenia treated with clozapine. It also supports the study of procholinergic agents, such as M1 receptor-positive allosteric modulators, to enhance cognition in schizophrenia.
AuthorsTarek K Rajji, Benoit H Mulsant, Simon Davies, Sawsan M Kalache, Christopher Tsoutsoulas, Bruce G Pollock, Gary Remington
JournalThe American journal of psychiatry (Am J Psychiatry) Vol. 172 Issue 6 Pg. 579-85 (Jun 2015) ISSN: 1535-7228 [Electronic] United States
PMID25859763 (Publication Type: Journal Article)
Chemical References
  • norclozapine
  • Clozapine
Topics
  • Adult
  • Aged
  • Clozapine (adverse effects, analogs & derivatives, blood, pharmacokinetics, therapeutic use)
  • Female
  • Humans
  • Male
  • Memory, Short-Term (drug effects)
  • Middle Aged
  • Neuropsychological Tests (statistics & numerical data)
  • Psychometrics
  • Psychotic Disorders (blood, diagnosis, drug therapy, psychology)
  • Schizophrenia (blood, diagnosis, drug therapy)
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: